SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is actively trending due to breaking news of a Department of Justice criminal probe into Fed Chair Jerome Powell, which the community widely perceives as unprecedented political pressure on the central bank. This development is sparking intense debate among investors about the Federal Reserve's independence and its potential impact on future monetary policy, raising concerns about market stability and the dollar's credibility.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following its CES 2026 showcase, where it unveiled significant advancements in agentic voice and visual AI, including new partnerships with TomTom for multi-agent navigation and Richtech Robotics for automated food systems. The community is actively discussing these innovative applications in automotive and robotics, fueled by ongoing speculation about a potential short squeeze due to the stock's high short interest. Investors are keenly watching SOUN's position in the expanding AI market, highlighting its unique white-label solutions as a competitive advantage.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is drawing significant attention following its preliminary quarterly and full-year results, which reportedly surprised the market with strong revenue and improved adjusted EBITDA. The community is actively debating whether these positive developments, coupled with substantial insider buying and a notably low share float, signal a potential short squeeze or if lingering concerns about the company's cash position and dilution risks will temper sustained upside.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is currently trending due to heightened competitive pressures in the weight-loss market, specifically Amazon Pharmacy's offering of Novo Nordisk's oral GLP-1 at competitive prices, a product HIMS currently lacks. This news, compounded by a recent analyst downgrade, has driven significant bearish sentiment and a notable price correction. However, a segment of the community views the dip as an oversold opportunity, emphasizing HIMS' long-term strategy in personalized healthcare, proprietary compounding labs, and international expansion beyond just weight-loss treatments.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum after announcing a record total contract value exceeding $1.1 billion for 2025, fueled by data agreements with over 70 pharmaceutical and biotech companies. This major business development highlights the strength of its AI-driven precision medicine platform, sparking widespread community excitement and further institutional interest in its role in advancing drug discovery and development.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as news circulates about a federal investigation into the Federal Reserve Chair, which is widely seen by the community as political pressure potentially undermining the central bank's independence. This has ignited debate among investors regarding its potential market impact on tech and growth stocks, though a "buy the dip" mentality is also evident.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a top trending stock as its highly anticipated earnings report approaches, with investors keenly awaiting commentary from Jamie Dimon regarding both strong profits and the economic outlook. The recent proposal to cap credit card interest rates is fueling significant debate on bank profitability, while JPM's warning on higher 2026 expenses has caused a notable dip. This dip is viewed by some as a buying opportunity, contrasting with concerns over rising costs and community discussions around potential silver short positions.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending amidst intense takeover speculation, notably involving Eli Lilly, following compelling Phase 3 data for its ulcerative colitis drug, obefazimod. The community is buzzing with discussions about potential significant acquisition offers and the drug's blockbuster market potential, positioning ABVX as a highly sought-after biotech asset. This M&A interest is further amplified by strong analyst confidence in obefazimod's differentiated profile within the competitive inflammatory bowel disease sector.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing extreme volatility following news of a new manufacturing partnership and a $10 million private placement, sparking intense debate between its operational progress and immediate dilution concerns. Community discussion centers on the potential for a massive short squeeze, with many comparing it to previous low-float runners, while others caution about dilution from the recent offering and the stock's significant price fluctuations.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as the community anticipates potential strategic updates from management at an upcoming healthcare conference, intensifying discussions around its perceived undervaluation and calls for new partnerships or a buyout. Investors are keenly focused on the company's protein-based vaccine platform and advanced adjuvant technology, while high short interest adds to the debate over its near-term trajectory amidst a dynamic biotech market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Mereo BioPharma Group (NASDAQ:MREO) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen lowered Mereo BioPharma Group from a "hold" rating to a "sell" rating in a report on Saturday...

Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO)

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 4,381 call options on the...

RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint

Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.

Nasdaq Falls Over 100 Points Amid Decline In Tech Stocks: Investor Sentiment Weakens, Fear & Greed Index In 'Neutral' Zone

U.S. stocks fell on Monday, with Nasdaq down 100 points. Nvidia Corp. and Mereo BioPharma Group plc also experienced declines.read more...

<ul class="summary-bullets"><li>The company said that results from the Phase 3 Orbit and Cosmic studies for an experimental drug designed to help people with brittle bone disease did not significantly reduce annualized clinical fracture rates.</li><li>Both studies showed improvements in bone mineral density, the company said.&nbsp;</li><li>Ultragenyx also noted that it will reduce expenses significantly after evaluating its planned operations.</li></ul>Ultragenyx Pharmaceutical Inc. (RARE) shares plunged over 41% on Monday after the company announced disappointing results from its Phase 3 studies for its experimental drug designed to help people with brittle bone disease.The company said that results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI), conducted in partnership with Mereo Biopharma (MREO), did not significantly reduce annualized clinical fracture rates compared to placebo or bisphosphonates, respectively. However, both studies showed improvements in bone mineral density, the company said.The firm also said it will significantly reduce expenses after evaluating its planned operations.<h2 class="st-heading-2">Trial Details</h2>In the Orbit study, participants showed substantial improvements in bone mineral density compared with the placebo group. However, that did not result in a significant reduction in annualized fracture rates, since the placebo group also had a low fracture rate, the company noted.In the Cosmic study, which included pediatric patients, the baseline fracture rate was substantially higher than in the Orbit patient group. While the study showed improvements in bone mineral density and a reduction in annualized fracture rate compared to bisphosphonate-treated patients, the results were not statistically significant.“We are surprised and disappointed by these results given the promising data from our Phase 2 study and the lack of approved treatment options available to patients with OI who live with significant pain, disability, and disease burden,” said Emil Kakkis, chief executive officer and president of Ultragenyx. “We continue to explore the data to gain deeper understanding of the findings.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RARE">RARE shares</a> jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. The stock was also among the top trending tickets on the platform.<figure class="image"><img style="aspect-ratio:1283/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_at_9_02_19_PM_png_233d427277.webp" alt="On Stocktwits, retail sentiment around RARE shares jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. " width="1283" height="153"></figure>Shares of RARE are down over 51% in the past year.Editor's Note: The story has been updated to reflect that the Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta was conducted in partnership with Mereo Biopharma.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did RARE Stock Plunge Over 41% Today?

Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program. 

Equity

Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows

Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta treatment.read more...

Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Mereo BioPharma Group (NASDAQ:MREO) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Mereo BioPharma Group in a research note on Monday...

Mereo BioPharma Group plc - Sponsored ADR $MREO Shares Bought by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. lifted its stake in shares of Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Free Report) by 20.7% during the second quarter, according to its most...

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Mereo Biopharma Group Plc - ADR

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

MREO
Mereo Biopharma

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MREO News

MREOMereo Biopharma